Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immuron ( (IMRN) ) just unveiled an announcement.
On February 17, 2026, Immuron Limited announced it had received an Australian Government Research and Development Tax Incentive cash refund of A$1.12 million for eligible R&D activities undertaken in the financial year ended June 30, 2025. The non-dilutive funding is intended to support growth in sales and profitability while preserving balance-sheet flexibility.
The company said the injection of cash will help it pursue profitability gains from its hyper-immune products, even as it increases investment in sales and marketing. Combined with cost reduction initiatives, Immuron is targeting an improvement in EBITDX excluding R&D in fiscal 2026, signaling a push toward stronger operating performance for shareholders within its niche infectious-disease and gastrointestinal therapeutics market.
The most recent analyst rating on (IMRN) stock is a Sell with a $0.68 price target. To see the full list of analyst forecasts on Immuron stock, see the IMRN Stock Forecast page.
Spark’s Take on IMRN Stock
According to Spark, TipRanks’ AI Analyst, IMRN is a Underperform.
The score is primarily held down by weak financial performance (declining revenue, persistent losses, and negative cash flows). Technical indicators also reflect a sustained downtrend with negative momentum. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
To see Spark’s full report on IMRN stock, click here.
More about Immuron
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases. Its lead marketed product is Travelan, an orally administered hyper-immune bovine colostrum tablet aimed at preventing travelers’ diarrhea, and it also distributes the IBS treatment device ProIBS in Australia and New Zealand while advancing pipeline candidate IMM-529 for recurrent C. difficile infection.
Average Trading Volume: 468,591
Technical Sentiment Signal: Sell
Current Market Cap: $6.45M
Learn more about IMRN stock on TipRanks’ Stock Analysis page.